Abstract: Mycobacterial diseases remain a significant cause of morbidity and mortality worldwide. Rifampicin and ethambutol are among the drugs recommended by WHO as first-line treatment. In this work, we addressed the question whether doses of the two anti-tuberculosis agents ethambutol and rifampicin transferred to a nursed infant could be of health concerns when the mother is under treatment. We used the approach of pharmacokinetic modelling using a structural model with two interconnected organisms: the first one being the organism of the nursing mother and the second one being the organism of the nursed child. Physiological data were taken from the literature. The models were parameterised by data from the literature concerning clearance, absorption and plasma/milk ratio. Distribution into the tissues was calculated by an algorithm. The predictive power of the model was tested by comparing the predicted plasma concentrations in the mothers with measured data from the literature. Comparison with measured data after direct infant treatment was performed for the rifampicin plasma concentrations predicted in the nursed infant. Both comparisons confirmed the appropriateness of the modelling results. The transfer of 0.08 mg/kg bw/day ethambutol via breast milk to the nursed infant, the dose we have estimated, when the mother received a therapeutic dose of 24.5 mg/kg bw, can be judged as being without health concern. Likewise, for rifampicin, the transferred dose of 0.4 mg/kg bw to the nursed infant resulting from a therapeutic dose of 10.9 mg/kg bw to the mother does not raise health concerns.
Mycobacterial diseases remain a significant cause of morbidity and mortality worldwide. They cause ill-health among millions of people each year and rank as the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). The latest estimates included in the WHO report [1] indicate almost 9 million new cases in 2011 and 1.4 million deaths because of tuberculosis. Four first-line drugs, isoniazid, rifampicin, ethambutol and pyrazinamide, are recommended by WHO [1] for the treatment of new cases of drug-susceptible tuberculosis. This treatment is effective and successful to reduce fatal outcomes in infected patients. A special situation is given in female patients who have given birth to a child concerning the safety of nursing with continuous treatment with the tuberculosis drugs. Continuous treatment is necessary to obtain effective levels, whereas interrupting treatment bears the risk of relapse. In this work, we tried to answer the question whether if the mother is treated the nursed infant would be exposed to doses of anti-tuberculosis agents which could be of concern for the baby. We decided to concentrate on ethambutol and rifampicin, two antituberculosis agents which are among the first-line drugs recommended by WHO [1] . In order to answer this question, it is necessary to estimate the exposure of the infant towards the drugs when the nursing mother is treated with therapeutic doses. We used pharmacokinetic modelling as an appropriate approach to answer the question. The model we have used consists of the model for a nursing female treated by oral administration of the drugs and their excretion into the milk and a second model for the nursed infant which drinks the milk and is exposed to the drugs by this route. We are able to model the amount the nursed infant is exposed to and also the concentration-time course in blood and body tissues in nursing mothers and their child taking into account also the immature excretory function in the nursed infants in the first three to 4 months (overview in ref [2] ).
Material and Methods
Model structure and differential equations. In the structural model which we used, the physiological structures are represented by tissue compartments. The model includes organs/tissues as well as arterial and venous blood. The organs are connected via blood flows, and the circulation system is closed via the lung and the heart. The structure of the physiologically based human model which we used to model several chemicals ([3] and [4] ) has previously been modified to simulate the plasma concentration in the nursing mother and the nursed child after oral exposure towards ethanol [5] . Owing to the special situation, we had to model two organisms: the first one being the organism of the nursing mother (structural model 1) and the second one being the organism of the nursed child (structural model 2). In the structural model of the nursing mother, we modelled the breast as an additional tissue. All physiological parameters (organ weight and blood flow through the organ) for the tissue compartments and also the weight of the lactating breast and the blood flow through the lactating breast were taken from [6] . In the structural model 2, we used the physiological data for a newborn [1] and no breast compartment was included. Thus, whereas the structural model 1 contains eight compartments, the structural model 2 contains seven compartments.
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The rate of change of concentration is described by the equa-
metabolizing tissues, where V T denotes the volume of tissue T, C T the concentration in tissue T, Q T the blood flow through tissue T, and C A the concentration in the arterial blood. C VT ¼ CT PT describes the concentration in the venous blood leaving the tissue, with P T as the tissue: blood partition coefficient.
Partition coefficients. For calculation of the partition coefficient (P T ) between tissues and blood, the algorithm of Schmitt [7] was used. This algorithm is based on physiological considerations concerning the factors influencing the partitioning between the molecules in plasma and in the cell considering that it is the concentration of the unbound fraction in plasma water and in the intracellular water which is in equilibrium. Binding to plasma proteins can be considered as independent of substance concentration as the number of binding sites on the main plasma protein albumin is infinitively large, compared to the molar concentration of the drug or chemical in question as long as the plasma albumin concentration remains within the normal range. There are exceptions when binding occurs to specific plasma proteins, which is not known for ethambutol being bound to albumin only. Also for the binding of a substance in a given tissue, it can generally be assumed to be determined by unspecific binding and the partition coefficients can be considered concentration independent in the concentration range which is of biological relevance. The main constituents in the cell which contribute to the binding are proteins and lipids, whereby it is to be distinguished between neutral lipids and phospholipids, the latter being further subdivided into those which possess an overall neutral head group with two oppositely charged moieties and those carrying only the negative charge of the acidic phosphate group. It is also important to consider that only the uncharged fraction of the molecules can diffuse freely and this can be taken into consideration taking into account the pH differences in plasma and intracellular space and applying the HendersonHasselbalch equation to calculate the unbound fraction.
The algorithm [7] uses for every tissue the tissue-specific composition for water, proteins, neutral lipids and phospholipids and considers pH dependency. The algorithm captures only physical processes of the distribution which depend on the physicochemical properties of the drug or chemical in question. The algorithm does not capture a transport process by transporter proteins against a concentration gradient. However, the predictions using the algorithm are similar to the experimental results as shown in the publication [7] . The algorithm is also recommended as one of the helpful and usable tools for prediction of partition coefficient between blood and tissues in a report on a joint EPAA-EURL ECVAM ADME workshop [8] . Details on concept and the formulas used are found in ref [7] .
Ethambutol.
Specific model structure. Ethambutol is mainly excreted unchanged in the urine, and a smaller proportion of the dose is metabolised to unknown metabolites. Hence, for ethambutol, the excretion is modelled by excretion via the kidneys and by metabolism in the liver (non-renal clearance) in both structural models (nursing mother and nursed infant). In structural model 1 (nursing mother), an additional excretion pathway is modelled as excretion by milk from the breast compartment. Thus, in model 1, there were three excretory compartments, liver, kidney and breast; in model 2, the excretory compartments were liver and kidney ( fig. 1 ).
Kinetic parameters. To parametrise the excretory pathways of ethambutol, we used published data in humans [11] . According to this publication, the renal clearance is 29.8 L/hr and the total clearance is 37.5 L/hr. We calculated the metabolic clearance as the difference between total and renal clearance as in the study of ref [11] , the drug Fig. 1 . Structure of the model. Note that the model of the mother's organism contains a breast compartment from which the milk transfers the substance via a milk dose compartment to the baby where it enters the gastrointestinal tract and then the liver. Metabolism is the route of elimination which is taking place in the liver in both the mother and the child. The metabolism in the child is scaled down according to the data found in ref [9] for ethambutol and according to data found in ref [10] .
was administered by intravenous infusion allowing such calculation. The metabolic clearance resulted in a value of 7.7 L/hr. For the nursed infant, the clearances in the adult had to be adjusted to account for the immature metabolic capacity and the immature renal excretory function. Data on the clearance of ethambutol specifically in the age group of infants were found in ref [9] after oral dosing. The mean clearance/fraction absorbed was 4.69 L/hr/kg bw (range 2.13 L/hr/ kg bw and 12.45 L/hr/kg bw) in children aged 6.6 AE 3.3 months. Taking the mean value of 4.69 L/hr/kg bw, a weight of 3.5 kg (weight of a newborn according to [6] ) and a fraction absorbed of 80% [11] , the clearance would be 13.1 L/hr which is 35% of the clearance in the adult (37.5 L/hr). As in adults, 80% of the total clearance is renal clearance and 20% metabolic clearance, for the estimation of renal and metabolic clearance in newborns, we attributed 80% of 13.1 L/hr to renal clearance (=10.5 L/hr) and the remainder to metabolic clearance (=2.6 L/hr).
The 'excretion' of ethambutol into the breast milk was modelled by excretion into a closed reservoir with a rate of 0.185 L/kg bw of the infant/day multiplied by the concentration in the milk. 0.185 L/kg bw/ day is the average of the amount of milk which is consumed per day by exclusively breast-fed infants between 8 days and 4 months [2] . The concentration in the milk is calculated by multiplying the concentration in the plasma of the nursing mother with the milk/plasma ratio. For ethambutol, experimental data on milk/plasma ratio are scarce. In [12] , two data pairs are reported as a personal communication. One was 1.4 mg/L in the milk and 1.5 mg/L in plasma, and the other was 4.6 mg/L in plasma and 4.6 mg/L in milk. These data seem to be the only concentrations of ethambutol measured in breast milk. From these measurements, we estimated the ratio milk/plasma as 1.
In both structural models, oral absorption of ethambutol was set as 80% [11] and oral absorption half-life was assumed to be 60 min. based on the time to maximum concentration of drug in serum (t max ) of 2.5 AE 0.9 hr in the publication of ref [13] .
In structural model 2 (nursed infant), intakes were by nursing with the milk produced in the breast of the nursing mother and containing ethambutol. Intake was from the reservoir which was opened at nursing time. Nursing was every 4 hr, and the time for nursing was set to 30 min.
Partition coefficients. For ethambutol, the P T -values for the tissues in the model were calculated using logP = À0.3 [14] and a pKa of 9.49, and a non-protein-bound fraction of 0.25 [11] .
Dose. For ethambutol, we selected a dose of 24.5 mg/kg bw (median dose in the study of ref [15] ).
Rifampicin.
Specific model structure. Rifampicin is mainly excreted via metabolism. Hence, for rifampicin, the excretion is modelled by metabolism in the liver in both structural models (nursing mother and nursed infant). In structural model 1 (nursing mother), an additional excretion pathway is modelled as excretion by milk from the breast compartment. Thus, in model 1 (nursing mother), there were two excretory compartments, liver and breast; in model 2 (nursed infant), the liver is the only excretory compartment ( fig. 1 ).
Kinetic parameters. For the excretion of rifampicin, we used the metabolic clearance data from studies in humans [10] : 9.3 L/hr for the nursing mother and 1.8 L/hr for the infant. The 'excretion' of rifampicin into the breast milk was modelled as for ethambutol by excretion into a closed reservoir with a rate of 0.185 L/kg bw/day. Data on milk/plasma ratio for rifampicin are scarce. In [12] , two data pairs are reported [16, 17] . One was 3.4-4.9 mg/L in the milk and 21.3 mg/L in plasma, and the other was 10-30 mg/L in milk and 50 mg/L in plasma. These data are from reviews, and it is unclear how the measurements were taken. In the first data pair, the ratio was 0.16-0.23, and in the second, it was 0.2-0.6. An alternative to estimate the milk/plasma ratio is to use an algorithm, described by [18] . Using this algorithm, the ratio of the unbound concentrations of rifampicin in milk/plasma is 0.4. For our modelling, we have used the calculated value of 0.4.
In both structural models, oral absorption of rifampicin was set to 100% [19] and oral absorption half-life was assumed to be 60 min. based on the time to maximum concentration of drug in serum (t max ) of 2.5 hr in the publication of ref [15] .
In structural model 2 (nursed infant), intakes were by nursing with the milk produced in the breast of the nursing mother and containing rifampicin. Intake was from the reservoir which was opened at nursing time. Nursing was every 4 hr, and the time for nursing was set to 30 min.
Partition coefficients. For rifampicin, the P T -values for the tissues in the model were calculated using logP = 2.7 [14] and a pKa of 1.7, and a non-protein-bound fraction of 10% [20] .
Dose. For rifampicin, we selected a dose of 10.9 mg/kg bw (median dose in the study of ref [15] ).
Evaluation. The appropriateness of the models for ethambutol and for rifampicin could be tested for the model describing the body of the nursing mother. The evaluation was made by comparing the modelpredicted concentration-time profile with the empirical data as published by [15] . Validation of the model in the infant could be made by comparison of the modelled peak concentration in the infant model with peak concentrations measured in infants (age 23 days; born at a mean gestational age of 35 weeks with a birth weight of 2.02 kg) treated with rifampicin [10] .
The values used to parameterise the models are given in table 1. All calculations were performed with MATLAB 8.0 (The MathWorks, Inc. Natick, Massachusetts, USA).
Sensitivity analysis. To identify the most influential parameters in the model, a sensitivity analysis was performed. For the relative increase of 10% of the parameter under consideration, the relative change of the peak blood concentration was determined. The quotient of these relative changes (i.e. the normalised sensitivity coefficient) characterises the strength of the influence of the variation of a single parameter [21] . The target of the sensitivity analysis was the peak plasma concentration of the mother for the following parameters: dose, partition coefficient (P) into fat, liver, kidney and brain as well as volume and blood flow for these organs, whereas it was the peak plasma concentration of the infant for the milk/plasma ratio and the infant bioavailability.
Results

Ethambutol.
Validation of the model in the adult person could be made by comparison of the modelled concentration-time profile with the results measured in patients in the study of ref [15] where a mean dose of 24.5 mg/kg bw was given, the same dose as we used for modelling ( fig. 2) . The high variability in the patient data can be explained by the variable doses in the patients which ranged from 16.8 to 32.6 mg/kg bw and by the naturally occurring variability in the factors determining the kinetics, in particular the elimination pathways (see also output of the sensitivity analysis for the most influential factors). It can be seen from fig. 2 that there is good agreement between predicted and measured values in the study of ref [15] .
Modelled oral exposure to 24.5 mg/kg bw ethambutol yielded predicted maximum blood concentrations in the nursing mother of 3.7 mg/L ( fig. 3A ) and of 0.1 mg/L ( fig. 3B ) in the nursed infant. It can be demonstrated that the concentration in the blood of the newborn slightly accumulates from 0.085 mg/L on the first day up to 0.098 mg/L on day 4.
The total dose the nursed infant was exposed to was predicted to be 0.28 mg/day or 0.08 mg/kg bw/day for a newborn infant.
Rifampicin.
Validation of the model in the adult person could be made by comparison of the modelled concentration-time profile with the results measured in patients in the study of ref [15] where a mean dose of 10.9 mg/kg bw was administered. The high variability in the patient data can be explained by the variable doses the patients received ranging from 8.8 to 14.2 mg/ kg bw. In addition, it is well known that the elimination pathways are characterised by an individual variability (see also output of the sensitivity analysis for the most influential factors). It can be seen from fig. 4 that there is good agreement between predicted and measured values in the study of ref [15] .
Modelled oral exposure to 10.9 mg/kg bw rifampicin yielded predicted maximum blood concentrations in the nursing mother of 3.2 mg/L ( fig. 5A ) and of 0.21 mg/L ( fig. 5B ) in the nursed infant.
The total dose the nursed infant was exposed to per day was predicted to be 1.4 mg or 0.4 mg/kg bw/day. In the Fig. 2 . Assessment of the model by comparing the modelled concentration-time curve (blue line) with experimental data from a study by [15] .
model, the peak concentration was 0.2 mg/L with a dose of 0.4 mg/kg bw. Assessment of the appropriateness of the model was performed for the infant by scaling up the dose of 0.4 mg/kg bw which resulted from the intake of rifampicin with milk to 10 mg/kg bw, the dose the infants received in the study of ref [10] . With our model, we would predict a concentration of 5.0 mg/L which compares well with the measured peak concentrations ranging from 3.2 to 6.8 mg/L [10] .
Sensitivity analysis of the concentration ratios. As expected, the parameter with the highest impact on the peak plasma concentration of rifampicin in the mother (+10.4%) was the dose, followed by the clearance (À7.2%) and the partition coefficient of the liver (À7.3%). The changes in the further parameters do not significantly alter the peak concentration. A 10% increased milk/plasma ratio did increase the peak plasma concentration in the infant (+9.6%) which is to be expected. In the same way, a change in infants' bioavailability had an impact on the peak concentration. Thus, from the kinetic parameters, clearance is the most influential factor for the peak concentration in the mother and milk/plasma ration and bioavailability in the infant (fig. 6 ).
The parameter with the highest impact on the peak plasma concentration of ethambutol in the mother (+9.9%) was the dose, followed by the partition coefficient of the liver (À3.79%) and the clearance (À3.67%). Like in rifampicin, the changes in the further parameters do not significantly alter the peak concentration. A 10% increased milk/plasma ratio did increase the peak plasma concentration in the infant (+9.7%) which is to be expected. Thus, from the kinetic parameters, clearance is the most influential factor for the peak concentration in the mother. In the same way, a change in infants' bioavailability had an impact on the peak concentration. Thus, from the kinetic parameters, clearance is the most influential factor for the peak concentration in the mother and milk/plasma ration and bioavailability in the infant ( fig. 6 ).
All the observed changes are indicating a modest influence of the parameters which are the most influential ones.
Discussion
In this study, we aimed at investigating the dose of ethambutol and rifampicin a nursed infant would be exposed to when the nursing mother would be treated for tuberculosis. For 4 . Assessment of the model by comparing the modelled concentration-time curve (blue line) with experimental data from a previous study [15] .
ethambutol, microbial killing is concentration-dependent, while resistance suppression correlates best with the percentage of the dosing interval in which the drug concentration is above the minimal inhibitory concentration (TMIC) [22, 23] . Rifamycins to which rifampicin belongs have concentration-dependent activity against Mycobacterium tuberculosis in vitro and in murine models [24] . Thus, the dosing in the mother cannot be changed as a reduced dose would threaten the therapeutic success. Insofar, it is important to discuss possible adverse effects in the nursed infants related to the doses of ethambutol and rifampicin which we have estimated by our modelling approach. The sensitivity analysis demonstrates that, as expected, the dose is influential as the partition coefficients, volumes and blood flow rates on the concentrations are irrelevant in all tested tissues with the notable exception of the liver. As expected, an increase in clearance and the partition coefficient of the liver was followed by decreased plasma concentrations. Alterations in the milk/plasma ratio have an almost linear effect on the concentration yielded in the nursed infants as had increase in bioavailability in the infant.
The quality of the modelling procedure is documented by the good agreement between predicted concentrations by the model and the measured concentrations in the clinical study by [15] for both ethambutol and rifampicin and for the child model for rifampicin by comparison of the model prediction with measure concentrations in ref [10] . Thus, the dose we calculated for the nursed infant can be taken as an appropriate estimation of the true value. In a population-based kinetic analysis, Zvada et al. [25] showed rapid maturation of the metabolic clearance of rifampicin in children, reaching 90% of the adult values (8.15 L/hr in their study) within 2 months.
The clearance values (1.8 L/hr) we took from the publication of ref [10] were estimated in a premature infant population and describe the lower end of the clearances in the infant population. Thus, the simulated concentrations in the infant are relevant for the very early post-natal period. The amount of drug which is transferred by the milk to the nursed infant is a relevant parameter for assessing potential adverse health effects arising from nursing of mothers treated with the drug.
For ethambutol, side effects have been noted and the most severe side effect is ocular toxicity for which a dose dependency has been shown [26] . With doses lower than 30 mg/kg/day, the prevalence of this toxicity was strongly reduced when compared with doses higher than 35 mg/kg/day. Dose dependency of ocular toxicity was confirmed in a recent study in Taiwanese patients [27] and in Korean patients in which doses below 12.3 mg/kg bw/day did elicit this side effect which is reversible only in rare cases [28] . It therefore seems safe to say that ocular toxicity is not expected to occur at a dose as low as 0.08 mg/ kg bw/day which we estimated for the nursed infant.
For rifampicin, the lowest recommended dose in infants is 10 mg/kg bw/day which is 25 times higher than the dose of 0.4 mg/kg bw/day we have estimated by which the nursed infant is exposed. A dose of 600 mg rifampicin per day in an adult (8.2 mg/kg bw/day) is typically used to investigate induction of cytochrome enzymes (CYPs), mainly CYP 3A4 [29, 30] . This dose is also more than 20 times higher than the dose transfer via breast milk to the nursed infant. From those data, it can be concluded that the exposure with rifampicin by nursing is safe for the nursed infant.
It is not surprising that the amount of the anti-tuberculosis agents that were excreted in the milk was low as the transfer from plasma/blood to milk was below 1 for ethambutol and also lower than 1 for rifampicin. However, due to the immature renal and metabolic excretion in newborns, even a low daily dose might accumulate to levels in plasma which could be of concern. We showed that despite the immature excretion pathways, the two anti-tuberculosis agents did not accumulate to a noticeable extent. The conclusions to be drawn from our data are in accordance with the review published by Tran and Montakantikul who based their considerations and conclusions on the limited amount of data which were available at the time [31] . Hence, based on the results using a more elaborated methodology, our results confirm the safe use of the two anti-tuberculosis drugs in mothers for their nursed infants, even at a very young age with impaired elimination/excretory function.
Conclusion
We have for the first time evaluated the amount of the antituberculosis agents ethambutol and rifampicin that would be transferred by breast milk to an exclusively breast-fed infant if the mother is treated with the drugs at therapeutic doses. Using a modelling approach, we conclude that the amount of drugs transferred to the infant does not raise any health concerns.
